Session Information
Session Title: Spondyloarthropathies and Psoriatic Arthritis II - Novel Treatments Psoriatic Arthritis
Session Type: Abstract Submissions (ACR)
|
(n=41) |
(n=41) |
(n=42) |
(n=41) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(–1.31, –0.55) –18.6 |
(–2.65, –1.88) –43.7 |
(–2.62, –1.87) –43.9 |
(–2.55, –1.76) –44.3 |
(95% CI) |
(–0.43, –0.09) –19.0 |
(–0.63, –0.29) –31.7 |
(–0.59, –0.26) –32.1 |
(–0.52, –0.17) –25.0 |
|
(–2.4, –0.3) –22.8 |
–72.0 |
(–3.7, –1.7) –60.0 |
(–3.7, –1.4) –59.5 |
|
(–1.5, –0.7) –44.0 |
(–1.6, –0.9) –72.2 |
(–1.8, –1.1) –77.8 |
(–1.5, –0.7) –61.1 |
|
(3.78) |
(2.1) |
(0.4) |
(1.53) |
(95% CI) |
(2.2, 22.2) |
(7.4, 31.6) |
(14.9, 42.2) |
(2.2, 22.2) |
|
Disclosure:
P. J. Mease,
AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene, Crescendo, Genentech, Jansses, Lilly, Merck, Novartis, Pfizer, UCB, Vertex,
2,
AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene, Covagen, Crescendo, Genentech, Jansses, Lilly, Merck, Novartis, Pfizer, UCB, Vertex,
5,
AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Crescendo, Genentech, Jansses, Lilly, Pfizer, UCB,
8;
A. B. Gottlieb,
Amgen, Astellas, Akros, Centocor (Janssen), Celgene, Bristol-Myers Squibb, Beiersdorf, Abbott Labs (AbbVie), Teva, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor, Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for,
5,
Centocor (Janssen), Amgen, Abbott (Abbvie), Novartis, Celgene, Pfizer, Lilly, Coronado, Levia, Merck,
2;
A. Berman,
None;
E. Drescher,
None;
J. Xing,
Bristol-Myers Squibb,
3;
S. Banerjee,
Bristol-Myers Squibb,
1,
Bristol-Myers Squibb,
3;
R. Wong,
Bristol-Myers Squibb,
1,
Bristol-Myers Squibb,
3.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-iib-randomized-double-blind-placebo-controlled-dose-ranging-multicenter-study-to-evaluate-the-efficacy-and-safety-of-clazakizumab-an-anti-il-6-monoclonal-antibody-in-adults-with-active/